Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies

Pharmacology and Therapeutics

Volumn 129, Issue 2, 2011, Pages 195-205

  Yuhki, Koh Ichi ^a   Kojima, Fumiaki ^a   Kashiwagi, Hitoshi ^a   Kawabe, Jun Ichi ^a   Fujino, Takayuki ^a   Narumiya, Shuh ^b   Ushikubi, Fumitaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cardiovascular diseases; Knockout mice; Prostaglandin; Prostanoids; Thromboxane

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PHOSPHOLIPASE A2; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTANOID; THROMBOXANE; THROMBOXANE A2;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CELL MEMBRANE; DISEASE COURSE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KNOCKOUT MOUSE; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOGENESIS; PRIORITY JOURNAL; TACHYCARDIA; THROMBOCYTE FUNCTION;

EID: 79151477508     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.09.004     Document Type: Review

References (167)

1. M. Abramovitz, M. Adam, Y. Boie, M. Carriere, D. Denis, and C. Godbout The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs Biochim Biophys Acta 1483 2000 285 293
2. 2α stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes J Biol Chem 271 1996 1179 1186
3. 2α in cultured neonatal rat ventricular myocytes Circ Res 83 1998 167 178
4. 4 receptor agonist protects against acute neurotoxicity Brain Res 1066 2005 71 77
5. 3 receptors exacerbates stroke and excitotoxic injury J Neuroimmunol 184 2007 172 179
6. A.S. Ahmad, S. Saleem, M. Ahmad, and S. Doré Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage Toxicol Sci 89 2006 265 270
7. 1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation Neurotox Res 14 2008 343 351
8. 2 receptors prevents NMDA-induced excitotoxicity J Neurotrauma 23 2006 1895 1903
9. 2 Biochem Biophys Res Commun 197 1993 263 270
10. E.M. Antman, J.S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K.A. Taubert Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association Circulation 115 2007 1634 1642
11. T. Asahara, T. Murohara, A. Sullivan, M. Silver, R. van der Zee, and T. Li Isolation of putative progenitor endothelial cells for angiogenesis Science 275 1997 964 967
12. J.A. Baron, R.S. Sandler, R.S. Bresalier, A. Lanas, D.G. Morton, and R. Riddell Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial Lancet 372 2008 1756 1764
13. H.J. Berger, B.L. Zaret, L. Speroff, L.S. Cohen, and S. Wolfson Regional cardiac prostaglandin release during myocardial ischemia in anesthetized dogs Circ Res 38 1976 566 571
14. G.R. Bernard, A.P. Wheeler, J.A. Russell, R. Schein, W.R. Summer, and K.P. Steinberg The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group N Engl J Med 336 1997 912 918
15. C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, and B. Davis Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 2000 1520 1528
16. 2 Nature 390 1997 622 625
17. 2 structure/function, mechanism, and signaling J Lipid Res 50 2009 S237 S242
18. L. Calabresi, G. Rossoni, M. Gomaraschi, F. Sisto, F. Berti, and G. Franceschini High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release Circ Res 92 2003 330 337
19. 2 receptor J Neuroinflammation 6 2009 5
20. P. Carmeliet, L. Moons, J.M. Stassen, M. De Mol, A. Bouche, and J.J. van den Oord Vascular wound healing and neointima formation induced by perivascular electric injury in mice Am J Pathol 150 1997 761 776
21. 2 Science 296 2002 539 541
22. Y. Cheng, M. Wang, Y. Yu, J. Lawson, C.D. Funk, and G.A. Fitzgerald Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function J Clin Invest 116 2006 1391 1399
23. 2+-dependent translocation domain with homology to PKC and GAP Cell 65 1991 1043 1051
24. J. Cohen The immunopathogenesis of sepsis Nature 420 2002 885 891
25. S.J. Coker, J.R. Parratt, I.M. Ledingham, and I.J. Zeitlin Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias Nature 291 1981 323 324
26. R.A. Coleman, S.P. Grix, S.A. Head, J.B. Louttit, A. Mallett, and R.L.G. Sheldrick A novel inhibitory receptor in piglet saphenous vein Prostaglandins 47 1994 151 168
27. R.A. Coleman, I. Kennedy, P.P.A. Humphrey, K. Bunce, and P. Lumley Prostanoids and their receptors J.C. Emmett, Comprehensive Medicinal Chemistry Vol 3: Membranes and receptors 1990 Pergamon Press Oxford, UK 643 714
28. O. Court, A. Kumar, and J.E. Parrillo Clinical review: Myocardial depression in sepsis and septic shock Crit Care 6 2002 500 508
29. M.J. Curtis, M.K. Pugsley, and M.J. Walker Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease Cardiovasc Res 27 1993 703 719
30. 4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries Br J Pharmacol 141 2004 580 585
31. E.A. de Deckere, D.H. Nugteren, and F. Ten Hoor Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart Nature 268 1977 160 163
32. X.F. Deng, D.G. Rokosh, and P.C. Simpson Autonomous and growth factor-induced hypertrophy in cultured neonatal mouse cardiac myocytes. Comparison with rat Circ Res 87 2000 781 788
33. S. Doré, T. Otsuka, T. Mito, N. Sugo, T. Hand, and L. Wu Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction Ann Neurol 54 2003 155 162
34. K.M. Egan, J.A. Lawson, S. Fries, B. Koller, D.J. Rader, and E.M. Smyth COX-2-derived prostacyclin confers atheroprotection on female mice Science 306 2004 1954 1957
35. T. Eichholtz, K. Jalink, I. Fahrenfort, and W.H. Moolenaar The bioactive phospholipid lysophosphatidic acid is released from activated platelets Biochem J 291 1993 677 680
36. 2 Science 193 1976 1135 1137
37. 2 inhibits cAMP production and promotes platelet aggregation J Clin Invest 107 2001 603 610
38. C.S. Facemire, R. Griffiths, L.P. Audoly, B.H. Koller, and T.M. Coffman The impact of microsomal prostaglandin E synthase 1 on blood pressure is determined by genetic background Hypertension 55 2010 531 538
39. H. Francois, K. Athirakul, D. Howell, R. Dash, L. Mao, and H.S. Kim Prostacyclin protects against elevated blood pressure and cardiac fibrosis Cell Metab 2 2005 201 207
40. H. Francois, K. Athirakul, L. Mao, H. Rockman, and T.M. Coffman Role for thromboxane receptors in angiotensin-II-induced hypertension Hypertension 43 2004 364 369
41. H. Francois, C. Facemire, A. Kumar, L. Audoly, B. Koller, and T. Coffman Role of microsomal prostaglandin E synthase 1 in the kidney J Am Soc Nephrol 18 2007 1466 1475
42. H. Francois, N. Makhanova, P. Ruiz, J. Ellison, L. Mao, and H.A. Rockman A role for the thromboxane receptor in L-NAME hypertension Am J Physiol 295 2008 F1096 F1102
43. 2 receptor IP J Clin Invest 114 2004 805 812
44. 2 J Biol Chem 277 2002 2614 2619
45. C.D. Funk, and G.A. FitzGerald COX-2 inhibitors and cardiovascular risk J Cardiovasc Pharmacol 50 2007 470 479
46. V.D. Garovic, and S.C. Textor Renovascular hypertension and ischemic nephropathy Circulation 112 2005 1362 1374
47. P. Golino, G. Ambrosio, B. Villari, M. Ragni, A. Focaccio, and L. Pace Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion J Am Coll Cardiol 21 1993 493 501
48. D.J. Grainger, L. Wakefield, H.W. Bethell, R.W. Farndale, and J.C. Metcalfe Release and activation of platelet latent TGF-β in blood clots during dissolution with plasmin Nat Med 1 1995 932 937
49. 2 analogue, on human blood platelet behaviour and vascular contractility Eur J Pharmacol 114 1985 129 137
50. D.P. Griese, A. Ehsan, L.G. Melo, D. Kong, L. Zhang, and M.J. Mann Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy Circulation 108 2003 2710 2715
51. S. Gross, P. Tilly, D. Hentsch, J.L. Vonesch, and J.E. Fabre Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors J Exp Med 204 2007 311 320
52. 2 receptor subtype 1 targeting J Clin Invest 117 2007 2496 2505
53. M. Hamberg, J. Svensson, and B. Samuelsson Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides Proc Natl Acad Sci USA 72 1975 2994 2998
54. C.M. Hao, and M.D. Breyer Physiological regulation of prostaglandins in the kidney Annu Rev Physiol 70 2008 357 377
55. 2 receptor Circulation 112 2005 84 92
56. 4 knockout mice Am J Physiol 298 2010 H623 H632
57. L.A. Harker Therapeutic inhibition of platelet function in stroke Cerebrovasc Dis 8 1998 8 18
58. R.C. Harris, and M.D. Breyer Physiological regulation of cyclooxygenase-2 in the kidney Am J Physiol 281 2001 F1 F11
59. A. Hartner, M. Goppelt-Struebe, and K.F. Hilgers Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension Hypertension 31 1988 201 205
60. T. He, T. Lu, L.V. d'Uscio, C.F. Lam, H.C. Lee, and Z.S. Katusic Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells Circ Res 103 2008 80 88
61. S. Heptinstall, D.I. Espinosa, P. Manolopoulos, J.R. Glenn, A.E. White, and A. Johnson DG-041 inhibits the EP3 prostanoid receptor-a new target for inhibition of platelet function in atherothrombotic disease Platelets 19 2008 605 613
62. 2 receptor Nature 349 1991 617 620
63. 4 improves cardiac function after myocardial ischaemia/reperfusion injury Cardiovasc Res 81 2009 123 132
64. 3 receptors in the reperfused ischemic pig heart J Mol Cell Cardiol 32 2000 285 296
65. R.S. Hotchkiss, and I.E. Karl Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis JAMA 267 1992 1503 1510
66. R.S. Hotchkiss, and I.E. Karl The pathophysiology and treatment of sepsis N Engl J Med 348 2003 138 150
67. C. Iadecola, K. Niwa, S. Nogawa, X. Zhao, M. Nagayama, and E. Araki Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate- mediated neurotoxicity in cyclooxygenase-2-deficient mice Proc Natl Acad Sci USA 98 2001 1294 1299
68. Y. Ikeda-Matsuo, Y. Hirayama, A. Ota, S. Uematsu, S. Akira, and Y. Sasaki Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischemic excitotoxicity Br J Pharmacol 159 2010 1174 1186
69. Y. Ikeda-Matsuo, A. Ota, T. Fukada, S. Uematsu, S. Akira, and Y. Sasaki Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury Proc Natl Acad Sci USA 103 2006 11790 11795
70. 2 ratios in unilateral renovascular hypertension of different severities Hypertension 38 2001 23 29
71. A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload Circulation 89 1994 2198 2203
72. 2 biosynthesis and renin release in the conscious dog J Pharmacol Exp Ther 222 1982 410 413
73. P.J. Jakobsson, S. Thorén, R. Morgenstern, and B. Samuelsson Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target Proc Natl Acad Sci USA 96 1999 7220 7225
74. B.L. Jensen, C. Schmid, and A. Kurtz Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells Am J Physiol 271 1996 F659 F669
75. 2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress Hypertension 52 2008 952 959
76. Z. Jia, A. Zhang, H. Zhang, Z. Dong, and T. Yang Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion Circ Res 99 2006 1243 1251
77. G. Johnson III, L.E. Furlan, N. Aoki, and A.M. Lefer Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats Circ Res 66 1990 1362 1370
78. 2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling Arterioscler Thromb Vasc Biol 30 2010 464 470
79. 1 receptors: downstream effectors of COX-2 neurotoxicity Nat Med 12 2006 225 229
80. 2 receptor Nat Med 5 1999 217 220
81. M. Kiriyama, F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells Br J Pharmacol 122 1997 217 224
82. 2 receptor signaling in the striatum J Neurosci 27 2007 12900 12907
83. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice J Clin Invest 114 2004 784 794
84. P. Kunapuli, J.A. Lawson, J.A. Rokach, J.L. Meinkoth, and G.A. FitzGerald Prostaglandin F2α (PGF2α) and the isoprostane, 8, 12-iso-isoprostane F2α -III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways J Biol Chem 273 1998 22442 22452
85. 2α induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo Am J Physiol 271 1996 H2197 H2208
86. A.M. Lefer, M.L. Ogletree, J.B. Smith, M.J. Silver, K.C. Nicolaou, and W.E. Barnette Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia Science 200 1978 52 54
87. D. Levy, R.J. Garrison, D.D. Savage, W.B. Kannel, and W.P. Castelli Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 322 1990 1561 1566
88. 2 receptor agonist, protects against cerebral ischemia Neurosci Lett 438 2008 210 215
89. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
90. X. Liu, M. Thangavel, S.Q. Sun, J. Kaminsky, P. Mahautmr, and J. Stitham Adenylyl cyclase type 6 overexpression selectively enhances β-adrenergic and prostacyclin receptor-mediated inhibition of cardiac fibroblast function because of colocalization in lipid rafts Naunyn Schmiedebergs Arch Pharmacol 377 2008 359 369
91. 2 receptor in permanent focal cerebral ischemia Ann Neurol 57 2005 758 761
92. D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, and G. De Simone Heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
93. C.D. Loftin, H.F. Tiano, and R. Langenbach Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2 Prostaglandins Other Lipid Mediat 68-69 2002 177 185
94. P.D. Lyden Thrombolysis for acute stroke Prog Cardiovasc Dis 42 1999 175 183
95. 3 Circulation 104 2001 1176 1180
96. P.W. Majerus Arachidonate metabolism in vascular disorders J Clin Invest 72 1983 1521 1525
97. Y. Manabe, J. Anrather, T. Kawano, K. Niwa, P. Zhou, and M.E. Ross Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity Ann Neurol 55 2004 668 675
98. 3 receptor attenuates ischemia-induced myocardial injury Circulation 112 2005 400 406
99. 4-receptor agonist Bioorg Med Chem 10 2002 2103 2110
100. 1 controls impulsive behavior under stress Proc Natl Acad Sci USA 102 2005 16066 16071
101. 2 receptor in cerebral ischemia J Neurosci 24 2004 257 268
102. H.R. Michie, K.R. Manogue, D.R. Spriggs, A. Revhaug, S. O'Dwyer, and C.A. Dinarello Detection of circulating tumor necrosis factor after endotoxin administration N Engl J Med 318 1988 1481 1486
103. S. Moncada, R. Gryglewski, S. Bunting, and J.R. Vane An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation Nature 263 1976 663 665
104. I. Morita Distinct functions of COX-1 and COX-2 Prostaglandins Other Lipid Mediat 68-69 2002 165 175
105. K.M. Mullane, and D. Fornabaio Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism Circ Res 62 1988 668 678
106. 2 synthase that acts in concert with cyclooxygenase-2 J Biol Chem 275 2000 32783 32792
107. T. Murata, F. Ushikubi, T. Matsuoka, M. Hirata, A. Yamasaki, and Y. Sugimoto Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Nature 388 1997 678 682
108. 3 determines G-protein specificity Nature 365 1993 166 170
109. S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid receptors: structures, properties, and functions Physiol Rev 79 1999 1193 1226
110. P. Needleman, P.S. Kulkarni, and A. Raz Coronary tone modulation: formation and actions of prostaglandins, endoperoxides, and thromboxanes Science 195 1977 409 412
111. W.H. Newman, M.B. Frankis, and P.V. Halushka Increased myocardial release of prostacyclin in dogs with heart failure J Cardiovasc Pharmacol 5 1983 194 201
112. W.W. Nichols, J. Mehta, T.J. Wargovich, D. Franzini, and D. Lawson Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist Angiology 40 1989 209 221
113. 4 triggers remodelling of the cardiovascular system at birth Nature 390 1997 78 81
114. 2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome J Am Soc Nephrol 16 2005 2354 2362
115. Y. Okada, A. Hara, H. Ma, C.Y. Xiao, O. Takahata, and Y. Kohgo Characterization of prostanoid receptors mediating contraction of the gastric fundus and ileum: Studies using mice deficient in prostanoid receptors Br J Pharmacol 131 2000 745 755
116. F. Oudot, A. Grynberg, and J.P. Sergiel Eicosanoid synthesis in cardiomyocytes: influence of hypoxia, reoxygenation, and polyunsaturated fatty acids Am J Physiol 268 1995 H308 H315
117. B.Z. Paul, B. Ashby, and S.B. Sheth Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells Br J Haematol 102 1998 1204 1211
118. M. Peters, N. Jeck, S. Reinalter, A. Leonhardt, B. Tönshoff, and G.ü. Klaus Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies Am J Med 112 2002 183 190
119. 4 receptor knockout mice with myocardial infarction Hypertension 51 2008 560 566
120. 4 prostanoid receptor signaling Life Sci 74 2003 143 153
121. R.H. Ritchie, R.J. Schiebinger, M.C. LaPointe, and J.D. Marsh Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide Am J Physiol 275 1998 H1370 H1374
122. H.A. Rockman, R.S. Ross, A.N. Harris, K.U. Knowlton, M.E. Steinhelper, and L.J. Field Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy Proc Natl Acad Sci USA 88 1991 8277 8281
123. R. Ross Atherosclerosis-an inflammatory disease N Engl J Med 340 1999 115 126
124. 2α FP receptor contributes to brain damage following transient focal brain ischemia Neurotox Res 15 2009 62 70
125. 3 receptor-deficient mice after cerebral ischemia J Neuroimmunol 208 2009 87 93
126. 1 receptor protects brain from ischemia-reperfusion injury Eur J Neurosci 26 2007 73 78
127. B. Samuelsson, R. Morgenstern, and P.J. Jakobsson Membrane prostaglandin E synthase-1: a novel therapeutic target Pharmacol Rev 59 2007 207 224
128. T. Sasaki, K. Kitagawa, K. Yamagata, T. Takemiya, S. Tanaka, and E. Omura-Matsuoka Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice J Cereb Blood Flow Metab 24 2004 107 113
129. J. Scheuer, and P. Buttrick The cardiac hypertrophic responses to pathologic and physiologic loads Circulation 75 Suppl. I 1987 I63 I68
130. K. Schrör, and C. Thiemermann Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177) Br J Pharmacol 87 1986 631 637
131. K. Schrör, K.C. Zimmermann, and R. Tannhäuser Augmented myocardial ischaemia by nicotine-mechanisms and their possible significance Br J Pharmacol 125 1998 79 86
132. E. Segi, Y. Sugimoto, A. Yamasaki, Y. Aze, H. Oida, and T. Nishimura Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice Biochem Biophys Res Commun 246 1998 7 12
133. T. Senbonmatsu, S. Ichihara, E. Price Jr., F.A. Gaffney, and T. Inagami Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload J Clin Invest 106 2000 R25 R29
134. R. Shibata, K. Sato, D.R. Pimentel, Y. Takemura, S. Kihara, and K. Ohashi Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms Nat Med 11 2005 1096 1103
135. P.J. Simpson, J. Mickelson, J.C. Fantone, K.P. Gallagher, and B.R. Lucchesi Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart Circ Res 60 1987 666 673
136. 2 are novel antiplatelet agents that do not prolong bleeding ACS Chem Biol 4 2009 115 126
137. W.L. Smith, D.L. DeWitt, and R.M. Garavito Cyclooxygenases: structural, cellular, and molecular biology Annu Rev Biochem 69 2000 145 182
138. T. Suzawa, C. Miyaura, M. Inada, T. Maruyama, Y. Sugimoto, and F. Ushikubi The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs Endocrinology 141 2000 1554 1559
139. T. Takahashi, C. Kalka, H. Masuda, D. Chen, M. Silver, and M. Kearney Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization Nat Med 5 1999 434 438
140. 2α mediate inflammatory tachycardia Nat Med 11 2005 562 566
141. Y. Takimoto, T. Aoyama, Y. Iwanaga, T. Izumi, Y. Kihara, and D. Pennica Increased expression of cardiotrophin-1 during ventricular remodeling in hypertensive rats Am J Physiol 282 2002 H896 H901
142. T. Tanabe, and V. Ullrich Prostacyclin and thromboxane synthases J Lipid Mediat Cell Signal 12 1995 243 255
143. 2 J Clin Invest 102 1998 1994 2001
144. M.A. Titheradge Nitric oxide in septic shock Biochim Biophys Acta 1411 1999 437 455
145. 2 biosynthesis J Clin Invest 119 2009 1477 1488
146. K.J. Tracey The inflammatory reflex Nature 420 2002 853 859
147. 2 in allergic response and parturition Nature 390 1997 618 622
148. Y. Urade, K. Watanabe, and O. Hayaishi Prostaglandin D, E, and F synthases J Lipid Mediat Cell Signal 12 1995 257 273
149. F. Ushikubi, M. Hirata, and S. Narumiya Molecular biology of prostanoid receptors; an overview J Lipid Mediat Cell Signal 12 1995 343 359
150. 2 receptor from human blood platelets J Biol Chem 264 1989 16496 16501
151. 3 Nature 395 1998 281 284
152. V.A. van de Schans, S.W. van den Borne, A.E. Strzelecka, B.J. Janssen, J.L. van der Velden, and R.C. Langen Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy Hypertension 49 2007 473 480
153. D.H. Walter, K. Rittig, F.H. Bahlmann, R. Kirchmair, M. Silver, and T. Murayama Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells Circulation 105 2002 3017 3024
154. H. Watanabe, T. Katoh, M. Eiro, M. Iwamoto, F. Ushikubi, and S. Narumiya Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene Circ J 69 2005 124 126
155. N. Werner, S. Junk, U. Laufs, A. Link, K. Walenta, and M. Bohm Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury Circ Res 93 2003 e17 e24
156. P. Wiesel, L. Mazzolai, J. Nussberger, and T. Pedrazzini Two-kidney, one clip and one-kidney, one clip hypertension in mice Hypertension 29 1997 1025 1030
157. S.C. Wong, M. Fukuchi, P. Melnyk, I. Rodger, and A. Giaid Induction of cyclooxygenase-2 and activation of nuclear factor-κB in myocardium of patients with congestive heart failure Circulation 98 1998 100 103
158. 2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors Circulation 104 2001 2210 2215
159. 4 Circulation 109 2004 2462 2468
160. 2 regulates vascular tone via its inhibitory effect on the expression of inducible nitric oxide synthase Circulation 108 2003 2381 2386
161. Y. Yatomi, F. Ruan, S. Hakomori, and Y. Igarashi Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets Blood 86 1995 193 202
162. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 2007 1121 1135
163. H. Yu, A.M. Gallagher, P.M. Garfin, and M.P. Printz Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression Hypertension 30 1997 1047 1053
164. 3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat Br J Pharmacol 126 1999 849 858
165. 3 receptor reduces myocardial infarct size in rodents Arterioscler Thromb Vasc Biol 19 1999 2141 2147
166. ATP-channels Eur J Pharmacol 367 1999 33 39
167. 2 receptors in the rat brain and neuronal responses to systemic inflammation Eur J Neurosci 11 1999 2651 2668